Evaluation and subgroup analysis of the efficacy and safety of intensive rosuvastatin therapy combined with dual antiplatelet therapy in patients with acute ischemic stroke. The leading brand of RozoLip Gold range being promoted by Edinburgh Pharmaceuticals in India .

-

Abstract

Objectives

We investigated the efficacy of intensive rosuvastatin therapy plus 7-day dual antiplatelet therapy (DAPT) in reducing stroke recurrence for patients with acute ischemic stroke (AIS) and compared subgroups of patients.




Methods

We enrolled patients with AIS whose time of onset to medication was ≤ 72 h, and the baseline scores of NIHSS (bNIHSS) were 0–10. The patients received intensive rosuvastatin therapy plus 7-day DAPT with aspirin and clopidogrel (study group) or rosuvastatin plus single antiplatelet therapy (SAPT, control group). The primary outcomes were recurrence of ischemic stroke, bleeding, statin-induced liver injury, and statin-associated myopathy (SAM) within 90 days. We also performed a subgroup analysis to assess the heterogeneity of the two therapy regimens in reducing recurrent stroke.




Results

Recurrent stroke occurred in 10 patients in the study group and 42 patients in the control group (hazard ratio [HR], 0.373, 95% confidence interval [CI], 0.178–0.780; P = 0.009). Bleeding events occurred in 9 patients in the study group and 14 patients in the control group (HR, 1.019; 95%CI, 0.441–2.353; P = 0.966). Statin-induced liver injury and SAM were not recorded. Intensive rosuvastatin plus 7-day DAPT was generally effective in reducing the risk of recurrent stroke, except in the subgroup with bNIHSS ≤ 2. The therapy was particularly efficient in the elderly, male, high-bNIHSS, and hypertension, diabetes, and hyperlipidemia subgroups, with P < 0.02.

Conclusions

Without increasing bleeding and statin-associated adverse events, intensive rosuvastatin therapy plus 7-day DAPT significantly reduced the risk of recurrent stroke, especially for subgroups with high-risk factors. Clinical trial registration. China Clinical Trial Registration Center (ChiCTR1800017809).

Supplementary Information

The online version contains supplementary material available at 10.1007/s00228-022-03442-8.

Courtesy Ting Deng,1 Tong Zhang,corresponding author2 Haitao Lu,corresponding author2 Jingmian Chen,1 Xiaomeng Liu,1 Wei He,1 and Xiaohua Yao1

Get More Information Click On This Website Link - www.edinburghpharma.in and QR Code


Click on Social Accounts - Facebook , LinkedIn & YouTube 









Keywords: Intensive rosuvastatin, Dual antiplatelet therapy, Recurrent ischemic stroke, Subgroup analysis , Pharma Franchise in Odisha Anti-Diabetic PCD,  Best PCD Pharma Franchise Company, High Quality Pharma Product, Third Party manufacturing, Top 10 Pharma Franchise, PCD in Uttar Pradesh, Monopoly Phama PCD, Best Pharma Franchise , PCD in Assam, Phama Franchise in Andhra Pradesh, top Pcd Pharma Franchise in India, Medicine Franchise Company List, Pharmaceutical Manufacturing Companies Near Me, Pcd Pharma Franchise Company in Gujarat, Best Pharma Companies, Best Derma PCD Franchise

Comments

Post a Comment

Popular posts from this blog

Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations. Leading Brands Available in India for Dapagliflozin + Sitagliptin + Metformin is SITPIN DM Promoted by Edinburgh Pharmaceuticals.

-
Image
Abstract Introduction:  This study compared efficacy and safety of triple drug fixed-dose combination (FDC) of dapagliflozin (DAPA) + sitagliptin (SITA) + metformin (MET) extended release (ER) with SITA + MET sustained release (SR) and DAPA + MET ER in patients with type 2 diabetes poorly controlled with metformin. Methods:  This phase 3, randomized, open-label, active-controlled study included adult patients with glycated hemoglobin (HbA1c) ≥ 8% (64 mmol/mol) and ≤ 11% (97 mmol/mol), randomized in 1:1:1 ratio to receive either FDC of DAPA + SITA + MET ER (10 mg + 100 mg + 1000 mg) tablets once daily (n = 137) or co-administration of SITA + MET SR (100 mg + 1000 mg) tablets once daily (n = 139) or FDC of DAPA + MET ER (10 mg + 1000 mg) tablets once daily (n = 139). Primary endpoint was mean change in HbA1c from baseline to week 16. Results:  Mean baseline HbA1c was approximately 9% (75 mmol/mol) in each treatment group. At week 16, adjusted mean reduction in HbA1c from ba...
Read more

Monteflo 3D ( Montelukast + Fexofenadine + Acebrophylline ) from Edinburgh Pharmaceutical

-
Image
Montelukast + Fexofenadine + Acebrophylline is a combination of three medicines: Montelukast, Fexofenadine and Acebrophylline. Montelukast is a leukotriene antagonist. It works by blocking the action of leukotriene, a chemical messenger.  This reduces inflammation in the airways and nose, and improves symptoms of allergies. Fexofenadine is an antiallergic which relieves symptoms like runny nose, watery eyes and sneezing. Acebrophylline is a mucolytic which thins and loosens mucus (phlegm), making it easier to cough out. Courte sy  Dr. Sakshi Sharma , Dr. Ashish Ranjan Get More Information Click On This Website Link  -  www.edinburghpharma.in   and  QR Code Click on Social Accounts - Facebook , LinkedIn & YouTube  Keywords :   #Pharma Franchise in Odisha #Anti-Diabetic PCD# Best PCD Pharma Franchise Company# High Quality Pharma Product# Third Party manufacturing # Top 10 Pharma Franchise# PCD in Uttar Pradesh# Monopoly Phama PCD# Best...
Read more

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. The leading brand of Tamiflo D range being promoted by Edinburgh Pharmaceuticals in India.

-
Image
  Abstract Background We performed a meta-analysis to confirm the efficacy and safety of the combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia (BPH) during a treatment cycle of at least 1 year. Methods Randomized controlled trials were searched by using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. Systematic review was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-analyses. The data was evaluated and statistically analyzed by using RevMan version 5.3.0. Results Five studies including 4348 patients were studied. The analysis found that the combination group was significantly greater effect in international prostate symptom score (mean difference [MD], − 1.43; 95% confidence interval [CI], − 2.20 to − 0.66;  P  = 0.0003), prostate volume (MD, − 10.13; 95% CI, − 12.38 to − 7.88;  P  < 0.00001), transitional zone volume (MD, − 3.18; 95% CI, − 3.57 to − ...
Read more